Document Type : Short Communication


Institute of Immunology and Human Genomics, Academy of Science of Republic of Uzbekistan, Tashkent, Uzbekistan



The COVID-19 pandemic has become a big challenge for the health systems of all countries. Since there were no reliable data on the efficacy of various drugs for COVID-19 in the early months of the pandemic, medical staff had to rely on constantly changing temporary recommendations and their experience in managing patients with COVID-19. In this regard, it is important to study the actions of medical personnel in a pandemic. In this study, we investigated the administration of drugs to treat COVID-19 in Uzbekistan. We demonstrated that physicians were swiftly adapting to new therapy recommendations; however, some drugs were not used appropriately, e.g., antibiotics and dexamethasone.


  1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. PMID: 32081636. PMCID: PMC7127800.
  2. World Health Organization. COVID-19 Weekly Epidemiological Update Global Overview Update 15 june. (2022).
  3. Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio Cuscó M, Ferrández O, Horcajada JP, et al. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti Infect Ther. 2021 Feb;19(2):147-163. doi: 10.1080/14787210.2020.1813024. PMID: 32853038.
  4. Ministry of healthcare of the Republic of Uzbekistan. Practical recommendations for the management of patients infected with COVID-19. 2020.
  5. Abaleke, E. et al. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 2021. 397, 605–612. doi: 1016/S0140-6736(21)00149-5. PMID: 33545096; PMCID: PMC7884931.
  6. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. PMID: 32194981. PMCID: PMC7078228.
  7. Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID. (2020).
  8. Flumignan RL, Civile VT, Tinôco JDS, Pascoal PI, Areias LL, Matar CF, Tendal B, Trevisani VF, Atallah ÁN, Nakano LC. Anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2022 Mar 4;3(3):CD013739. doi: 10.1002/14651858.CD013739. PMID: 35244208. PMCID: PMC8895460.
  9. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine 384, 693–704 (2021). doi:10.1056/NEJMoa2021436.
  10. World Health Organization. Guideline Clinical management of COVID-19 patients: living guideline, 23 june 2022. (2021).